Matches in SemOpenAlex for { <https://semopenalex.org/work/W2906317488> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2906317488 endingPage "S144" @default.
- W2906317488 startingPage "S143" @default.
- W2906317488 abstract "The April-2015 Spanish Strategic Plan for Hepatitis C Virus (SSP-HCV) established access to free-interferon direct-acting antivirals (DAAs). As hospital-delivered drugs, the main objective of this study is to analyze real-life budget impact of SSP-HCV in a Spanish Hospital Pharmacy Service (HPS). Retrospective study 3 years before (Pre: 2012/April-2015/March) and 3 after (Post: 2015/April-2018/March; Post-I: 2015/April-2016/March; Post-II: 2016/April-2017/March; Post-III: 2017/April-2018/March) SSP-HCV implementation, following the Ispor Good Practice for Budget Impact Analysis. Features of the health care system: universal-free access to interferon-based therapies or DAAs. Scope: health area with 550.000 inhabitants. Perspective: Public Health System (HPS). Eligible population: HCV-infected patients. Pre-SSP-HCV intervention: peginterferon±ribavirin±boceprevir/telaprevir (IFN-based). Post-SSP-HCV intervention: any free-interferon DDAs combination. Costs: direct drug costs (€). Time horizon: 3 years. Uncertainty and Scenario Analyses: parameter uncertainty in the input values contemplates a reduction of 10% -25% -50% of drug prices and no structural uncertainty was considered. Data sources: real-life use and cost data from registries or databases from HPS. 1. Drug cost Pre-SSP-HCV vs Post-SSP-HCV: 1a) Total drug costs: 201.625.160 € vs 263.664.011 €; 1b) HCV drug costs: 2.628.399 € vs 27.666.004 €. 2. Percentage HCV/Total drug costs: 2a) Pre: 1,3%; 2b) Post: 10,5%: 2c) Post-I: 17,5%; 2d) Post-II: 8,3%; 2e) Post-III: 4,5%. 3. HCV drug cost/patient: 3a) Pre: 7.104 €; 3b) Post: 16.380 €; 3c) Post-I: 22.714 €; 3d) Post-II: 16.789 €; 3e) Post-III: 7.287 €. 4. Real-life SSP-HCV budget impact: 4a) Post: 9,2%; 4b) Post-I: 16,2%; 4c) Post-II: 7,0%; 4d) Post-III: 3,2%. 5. Uncertainty and Scenario Analyses budget impact 3 years ahead: 5a) 10% DAAs-cost reduction: 2,9%; 5b) 25% DAAs-cost reduction: 2,4%; 5c) 50% DAAs-cost reduction: 1,6%. The April/2015 SSP-HCV has had a very high budget impact on HPS, but has been declining by 50% per annum since its implementation. Currently, DAAs cost/patient is like interferon-based therapy Pre-SSP-HCV. In a 3-year time horizon, the budgetary impact could be like Pre-SSP-HCV." @default.
- W2906317488 created "2019-01-01" @default.
- W2906317488 creator A5001289474 @default.
- W2906317488 creator A5001444684 @default.
- W2906317488 creator A5014503266 @default.
- W2906317488 creator A5018111427 @default.
- W2906317488 creator A5027990204 @default.
- W2906317488 creator A5046427885 @default.
- W2906317488 creator A5058402271 @default.
- W2906317488 creator A5062284049 @default.
- W2906317488 creator A5089069134 @default.
- W2906317488 date "2018-10-01" @default.
- W2906317488 modified "2023-10-18" @default.
- W2906317488 title "PGI13 - REAL-LIFE BUDGET IMPACT OF DIRECT-ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS IN AN SPANISH PUBLIC HOSPITAL PHARMACY" @default.
- W2906317488 doi "https://doi.org/10.1016/j.jval.2018.09.856" @default.
- W2906317488 hasPublicationYear "2018" @default.
- W2906317488 type Work @default.
- W2906317488 sameAs 2906317488 @default.
- W2906317488 citedByCount "0" @default.
- W2906317488 crossrefType "journal-article" @default.
- W2906317488 hasAuthorship W2906317488A5001289474 @default.
- W2906317488 hasAuthorship W2906317488A5001444684 @default.
- W2906317488 hasAuthorship W2906317488A5014503266 @default.
- W2906317488 hasAuthorship W2906317488A5018111427 @default.
- W2906317488 hasAuthorship W2906317488A5027990204 @default.
- W2906317488 hasAuthorship W2906317488A5046427885 @default.
- W2906317488 hasAuthorship W2906317488A5058402271 @default.
- W2906317488 hasAuthorship W2906317488A5062284049 @default.
- W2906317488 hasAuthorship W2906317488A5089069134 @default.
- W2906317488 hasBestOaLocation W29063174881 @default.
- W2906317488 hasConcept C104863432 @default.
- W2906317488 hasConcept C126322002 @default.
- W2906317488 hasConcept C138816342 @default.
- W2906317488 hasConcept C159047783 @default.
- W2906317488 hasConcept C159110408 @default.
- W2906317488 hasConcept C194828623 @default.
- W2906317488 hasConcept C2522874641 @default.
- W2906317488 hasConcept C2776408679 @default.
- W2906317488 hasConcept C2776455275 @default.
- W2906317488 hasConcept C2777159539 @default.
- W2906317488 hasConcept C2778159067 @default.
- W2906317488 hasConcept C2778390639 @default.
- W2906317488 hasConcept C2780040827 @default.
- W2906317488 hasConcept C2908647359 @default.
- W2906317488 hasConcept C512399662 @default.
- W2906317488 hasConcept C71924100 @default.
- W2906317488 hasConcept C99454951 @default.
- W2906317488 hasConceptScore W2906317488C104863432 @default.
- W2906317488 hasConceptScore W2906317488C126322002 @default.
- W2906317488 hasConceptScore W2906317488C138816342 @default.
- W2906317488 hasConceptScore W2906317488C159047783 @default.
- W2906317488 hasConceptScore W2906317488C159110408 @default.
- W2906317488 hasConceptScore W2906317488C194828623 @default.
- W2906317488 hasConceptScore W2906317488C2522874641 @default.
- W2906317488 hasConceptScore W2906317488C2776408679 @default.
- W2906317488 hasConceptScore W2906317488C2776455275 @default.
- W2906317488 hasConceptScore W2906317488C2777159539 @default.
- W2906317488 hasConceptScore W2906317488C2778159067 @default.
- W2906317488 hasConceptScore W2906317488C2778390639 @default.
- W2906317488 hasConceptScore W2906317488C2780040827 @default.
- W2906317488 hasConceptScore W2906317488C2908647359 @default.
- W2906317488 hasConceptScore W2906317488C512399662 @default.
- W2906317488 hasConceptScore W2906317488C71924100 @default.
- W2906317488 hasConceptScore W2906317488C99454951 @default.
- W2906317488 hasLocation W29063174881 @default.
- W2906317488 hasOpenAccess W2906317488 @default.
- W2906317488 hasPrimaryLocation W29063174881 @default.
- W2906317488 hasRelatedWork W1876982146 @default.
- W2906317488 hasRelatedWork W1970780167 @default.
- W2906317488 hasRelatedWork W1975576681 @default.
- W2906317488 hasRelatedWork W2020539659 @default.
- W2906317488 hasRelatedWork W202745368 @default.
- W2906317488 hasRelatedWork W2069762307 @default.
- W2906317488 hasRelatedWork W2094190427 @default.
- W2906317488 hasRelatedWork W2161030888 @default.
- W2906317488 hasRelatedWork W2417556805 @default.
- W2906317488 hasRelatedWork W2810818146 @default.
- W2906317488 hasVolume "21" @default.
- W2906317488 isParatext "false" @default.
- W2906317488 isRetracted "false" @default.
- W2906317488 magId "2906317488" @default.
- W2906317488 workType "article" @default.